4 Results for "

Ulcerogenic liability

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "Ulcerogenic liability" in MCE Product Catalog:

Cat. No.: HY-W002328
CAS No.: 1621-91-6
Pyrazole-3-carboxylic acid is an alternative anchoring group to carboxylic acid in phthalocyanine dyes. Pyrazole-3-carboxylic acid shows flexible coordination modes when coordinates with metal ions. Pyrazole-3-carboxylic acid can chelate to metal ions and form very stable complexes through its N and O atoms. Pyrazole-3-carboxylic acid can be used to synthesize derivatives that possess antibacterial, anti-inflammatory, ulcerogenic liability and antiproliferative activities .
loading...
    loading...
Cat. No.: HY-146167
Target:  

NO Synthase

Research Areas:  

Inflammation/Immunology

iNOS/PGE2-IN-1 (compound 4a), an iNOS/PGE2 inhibitor, is a potent anti-inflammatory agent. iNOS/PGE2-IN-1 can inhibit LPS-induced NO production. iNOS/PGE2-IN-1 possesses low ulcerogenic liabilities .
loading...
    loading...
Cat. No.: HY-184937
COX-2/CA II-1 is an orally active dual selective inhibitor targeting COX-2 and hCA II. COX-2/CA II-1 inhibits COX-2 with an IC50 value of 0.13 μM (SI = 9.25 vs COX-1) and hCA II with a Ki value of 39.1 nM (SI = 933.8 vs hCA I). COX-2/CA II-1 demonstrates significant analgesic and anti-inflammatory effects in animal models, shows improved gastric safety with reduced ulcerogenic liability, and exhibits intraocular pressure (IOP)-lowering effects in rabbit glaucoma models. COX-2/CA II-1 can be used for anti-inflammatory, analgesic and antiglaucoma research .
loading...
    loading...
Cat. No.: HY-184938
COX-2/CA II-2 is an orally active dual selective inhibitor targeting COX-2 and hCA II. COX-2/CA II-2 inhibits COX-2 with an IC50 value of 0.05 μM (SI = 12.02 vs COX-1) and hCA II with a Ki value of 62.6 nM (SI = 704.2 vs hCA I). COX-2/CA II-2 demonstrates significant analgesic and anti-inflammatory effects with rapid onset and sustained duration in animal models, shows improved gastric safety with reduced ulcerogenic liability, and exhibits a gradual intraocular pressure (IOP)-lowering effect without statistical significance relative to the sham-treated eye in rabbit glaucoma models. COX-2/CA II-2 can be used for anti-inflammatory, analgesic and antiglaucoma research .
loading...
    loading...